Jan. 24 at 3:44 AM
$TRVI Here is my two cents on what to expect in the short term with this awesome gem of a ticker. Jennifer should be announcing soon the results from her phase 3 study meeting with the FDA. As many of you know there is no approved therapy for chronic cough out in the market. I believe they give TRVI a fast track designation to bring this drug therapy for everyone who is suffering with chronic cough. Once the street hears this news we will see a nice move up, and analyst will start raising their price target. I believe this news is right around the corner, so we just need to be patient and do not expect any serious movement until that happens. JMO!
